Madeddu P, Oppes M, Soro A, Dessi'-Fulgheri P, Glorioso N, Bandiera F, Manunta P, Rubattu S, Troffa C, Tonolo G C
J Cardiovasc Pharmacol. 1987 May;9(5):536-40. doi: 10.1097/00005344-198705000-00005.
Despite their vasodilating action, calcium antagonists increase renal sodium excretion. To ascertain whether renal kallikrein plays a role in the renal effects of calcium antagonists, nifedipine (N) (10 mg orally) or placebo (P) was given to 17 male patients with mild to moderate essential hypertension during a 6-h infusion of either saline (S) or aprotinin (A) (2 X 10(6) KIU in 200 ml of saline). Blood pressure (BP) and heart rate (HR) were measured every 10 min, and blood samples were taken at -10, 0, 30, 60, 120, 240, 360 min for plasma renin activity (PRA), creatinine, and osmolarity determinations. Urinary kallikrein, aldosterone, creatinine, and electrolytes were measured in 6-h urine collections. The acute administration of N induced a significant systolic BP (SBP) and diastolic (DBP) fall and a transient PRA increase that peaked at 30 min and were not modified by A infusion. Urinary volume (+47%), Na+ (+54%) and Cl- (+58%) excretion were significantly enhanced by N. There were less pronounced and statistically not significant increases in urinary excretion of Ca2+ (+38%) and K+ (+29%). Infusion of A did not interfere with the natriuretic effect of N. Our data do not support the hypothesis that the kallikrein-kinin system plays an important role in mediating the renal effects of nifedipine in humans.
尽管钙拮抗剂具有血管舒张作用,但它们会增加肾脏钠排泄。为了确定肾激肽释放酶是否在钙拮抗剂的肾脏效应中起作用,在17名轻度至中度原发性高血压男性患者中,于6小时输注生理盐水(S)或抑肽酶(A)(2×10⁶KIU溶于200ml生理盐水中)期间,给予硝苯地平(N)(口服10mg)或安慰剂(P)。每10分钟测量一次血压(BP)和心率(HR),并在-10、0、30、60、120、240、360分钟采集血样,用于测定血浆肾素活性(PRA)、肌酐和渗透压。在6小时尿液收集样本中测量尿激肽释放酶、醛固酮、肌酐和电解质。急性给予N可使收缩压(SBP)和舒张压(DBP)显著下降,并使PRA短暂升高,在30分钟时达到峰值,且不受A输注的影响。N可显著增加尿量(+47%)、Na⁺(+54%)和Cl⁻(+58%)排泄。Ca²⁺(+38%)和K⁺(+29%)的尿排泄量虽有增加,但不太明显且无统计学意义。输注A并不干扰N的利钠作用。我们的数据不支持激肽释放酶-激肽系统在介导硝苯地平对人体肾脏效应中起重要作用这一假说。